Phase I/II of Durvalumab (MEDI4736) + Tremelimumab + Stereotactic Body Radiotherapy for Metastatic Head and Neck Carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 04 Sep 2018
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 24 Aug 2018 Planned primary completion date changed from 1 Dec 2019 to 31 Mar 2020.
- 24 Aug 2018 Status changed from not yet recruiting to recruiting.
- 19 Jun 2018 Planned initiation date changed from 1 May 2018 to 1 Jul 2018.